.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Post-Conference Perspectives: Advances in the Treatment of HSCT-TMA

EP. 1: Pathophysiology of HSCT-TMA

December 23rd 2019

EP. 2: Survival Outcomes in HSCT-TMA After Transplant

December 23rd 2019

EP. 3: Post-Transplant TMA: Survival with MASP-2 Inhibitors

December 23rd 2019

EP. 4: TMA Management: Agents That Inhibit Endothelial Cell Injury

December 23rd 2019

EP. 5: Future Directions For the Treatment of Transplant TMA

December 23rd 2019

EP. 6: A Retrospective Look at the Management of HSCT-TMA

December 23rd 2019

EP. 7: HSCT-TMA Management: Narsoplimab Clinical Trials

December 23rd 2019

EP. 8: The Role of Defibrotide to Inhibit Cell Injury

December 23rd 2019

EP. 9: FDA Approval in Myeloma, Priority Review in DLBCL, Application Accepted of a Biosimilar, and More

December 23rd 2019